Member Info for Patagucci

I thought it was a weird comment to make… but they made it. If by the end of the week we haven’t heard anything, it’s yet another disappointment from synairgen.

Just why make the comment?!

Why only post this on X now?

Hemogenyx Pharmaceuticals is pleased to announce that the IRB of the Company's first clinical site has granted approval to initiate a Phase I clinical trial of the Company's lead asset, HEMO-CAR-T, for the treatment of AML in adults.

Hopefully. Another positive RNS.

Check back in 6-8 weeks.

Thank you for your AGM report.

I keep an eye on this forum, like many I’m so disappointed with how this company played out. But I still have a glimmer of hope.

One thing I think is a little concerning, and I want to hear others opinions on this. Is the only way to now come out in profit, if you invested pre failed P2, to buy into this share raise which is inevitably coming. On the hope the next P2 and possibly P3, will be successful.

Simon is leaving and mark is coming in. But reading the end of this RNS is a little worrying

Full name:

Mark Parry-Billings

Age:

60

Shares held in the Company:

None

Current directorships:

None

Historic directorships in previous 5 years:

Atopix Therapeutics Limited

Zymenex Holding ApS

On 17 November 2016, Mark Parry-Billings was appointed as a director of Atopix Therapeutics Limited. The company was dissolved on 2 May 2024 following members' voluntary liquidation. There were no creditor losses.

On 31 January 2019, Mark Parry-Billings was appointed as a director of Zymenex Holding ApS. The company was dissolved on 3 December 2020 following voluntary liquidation. There were no creditor losses.

I certainly hope Synairgen isn’t liquidated and they have a plan! So much potential was here, I lost a lot of money and still find it hard to accept. Not to mention the potential lives that could have been saved.

With Synairgen's resources dedicated to the clinical development of SNG001, Dr. Marcin Mankowski became the Company's Chief Medical Officer in 2023 and will continue to lead the clinical development strategy for SNG001.

My answer to that; Has the drug changed? No. Will trials prove the drug has a use? Possibly. Is now a good time to invest? It is a high risk and speculative bet and I would say possibly. That’s why I haven’t sold my shares since the failed P2.

Maybe I’m being naive. But I stand by the fact the drug work, we just couldn’t prove it works any better than standard treatments.

Respiratory outbreaks will happen again. As do people suffering from viral exacerbations of COPD etc. SNG is still valuable.

Naewise- I agree. Nothing concrete just speculation. This company has in my eyes failed its shareholders in the last few years not updating us as often as we would like. If there is a reason they have though, it will all come out hopefully soon. I have low expectation, high hopes.

I’m very tempted to. It would cost 5% of what I originally paid for my shares to double my holding. The products not changed…

Patents often don’t get RNSd to my knowledge.

U.S. Application No. 17/133,448

Title: METHOD OF ELIMINATING HEMATOPOIETIC STEM CELLS/HEMATOPOIETIC

PROGENITORS (HSC/HP) IN A PATIENT USING BI-SPECIFIC ANTIBODIES

Applicant: HEMOGENYX LLC

Inventor: Vladislav Sandler

Issued as U.S. Patent No. 11,945,866 on April 2, 2024.

At 2.0p as well.

Disappointing. But long term if this gets the money raised to get to where we need to be I guess suck it up and look to the future.

“Research continues on CBR and the Company intends to increase its focus on this once HEMO-CAR-T has entered clinical trials.“

CAR-T is technically clinical right, although not started trials. What’s people’s thoughts? Selling off this part of the company to fund others.

Either way what a week for RNSs, trust in the science and the SP will follow.

When will the market wake up to this?

He has deleted his account…

A clinical stage company, that seems very undervalued and now Vlad has gone off Twitter. Weird, so much to be proud of here yet it all feels a bit muted.

Let’s go

JHFH, if they receive it, is Hemo/Vlad allowed to not RNS it. And wait until it’s better timing. Isn't that withholding sensitive information?

I thought once he receives it, it will be then and there or 7AM next working day.

Apologies, it’s not AIM, I don’t know why I thought it was.